Kabra Drugs Ltd Stock Price Today (NSE: KABRADG)
Fundamental Score
Kabra Drugs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Kabra Drugs Ltd share price today is ₹24.04, down 2.08% on NSE/BSE as of 3 August 2026. Kabra Drugs Ltd (KABRADG) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹51.49 (Cr). The 52-week high for KABRADG share price is ₹35.52 and the 52-week low is ₹15.50. At a P/E ratio of 10.38x, KABRADG is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 18.28% and a debt-to-equity ratio of 0.02.
Kabra Drugs Ltd Share Price Chart — NSE/BSE Historical Performance
Kabra Drugs Ltd share price chart: -1.12% return over the past month. 52-week high ₹35.52, 52-week low ₹15.50.
Kabra Drugs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹23.30 | ₹23.99 | ₹22.62 | ₹22.93 | 1.24L (Cr) | |
| ₹23.81 | ₹23.81 | ₹22.69 | ₹23.30 | 50.71K (Cr) | |
| ₹23.61 | ₹24.27 | ₹22.50 | ₹22.82 | 1.16L (Cr) | |
| ₹23.06 | ₹24.50 | ₹22.45 | ₹22.99 | 1.03L (Cr) | |
| ₹24.33 | ₹24.33 | ₹22.80 | ₹23.06 | 1.22L (Cr) | |
| ₹25.41 | ₹25.95 | ₹24.16 | ₹24.33 | 55.66K (Cr) | |
| ₹24.49 | ₹27.80 | ₹24.49 | ₹25.42 | 4.27L (Cr) | |
| ₹22.99 | ₹24.40 | ₹22.60 | ₹23.66 | 2.02L (Cr) | |
| ₹24.17 | ₹24.69 | ₹23.00 | ₹23.10 | 1.56L (Cr) | |
| ₹24.95 | ₹25.00 | ₹23.36 | ₹23.88 | 89.08K (Cr) |
Kabra Drugs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹23.61 | ₹24.27 | ₹22.50 | ₹22.93 | -2.88% | |
| ₹25.90 | ₹28.35 | ₹20.10 | ₹22.99 | -11.24% | |
| ₹26.03 | ₹28.18 | ₹23.16 | ₹24.40 | -6.26% | |
| ₹24.58 | ₹29.45 | ₹23.30 | ₹26.03 | +5.90% | |
| ₹29.15 | ₹32.07 | ₹24.50 | ₹24.58 | -15.68% | |
| ₹28.90 | ₹35.52 | ₹27.64 | ₹30.52 | +5.61% | |
| ₹31.27 | ₹33.00 | ₹25.64 | ₹28.62 | -8.47% | |
| ₹32.64 | ₹32.66 | ₹25.46 | ₹30.55 | -6.40% | |
| ₹19.37 | ₹31.15 | ₹18.50 | ₹31.11 | +60.61% | |
| ₹17.85 | ₹20.49 | ₹15.50 | ₹18.92 | +5.99% | |
| ₹19.44 | ₹21.00 | ₹17.08 | ₹17.69 | -9.00% | |
| ₹21.10 | ₹21.41 | ₹17.40 | ₹18.52 | -12.23% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Zero promoter holding, stretched valuation, and microcap illiquidity make Kabra Drugs a high-risk gamble, not an investment.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Kabra Drugs board will meet on April 21, 2026, to consider Ms. Monam Kapoor as an Additional Director and major diversification plans. India Pharma 2026 concluded on April 15, 2026, with calls for enhanced funding and infrastructure to accelerate pharmaceutical innovation.
CORE STORY (THE REAL GAME)
- Q3FY26 PAT jump of 578% YoY
- Revenue increased 53.9% QoQ in Q3FY26
- Agreement to appoint 200 channel partners
- Successful diversification into medical equipment manufacturing
- Significant order wins in the medical equipment segment
- Positive regulatory approvals for new business streams
- Zero promoter holding
- History of losses and negative free cash flow of ₹-5.7 Cr over 5 years
- Microcap illiquidity: high price volatility and potential for manipulation
Zero FII, DII, or Promoter holding indicates a lack of institutional confidence.
The Indian pharmaceutical industry is undergoing a strategic shift towards innovation and domestic manufacturing, presenting both opportunities and challenges.
Kabra Drugs signed an agreement with MR Franchise to appoint 200 channel partners nationwide.
No: Free Cash Flow 5Y: ₹-5.7 Cr.
Kabra Drugs' future hinges on successful diversification and execution of its expansion plans. Failure to achieve these goals could lead to a significant correction in the stock price.
Primary Thesis Risk
Lack of promoter commitment and stretched valuation make this a high-risk, low-conviction play.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Kabra Drugs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Kabra Drugs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of KABRADG across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (18.28%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (20.80%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 10.38 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (171.79%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Excellent EPS Growth (48.00% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (96.85% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.02)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (191.67x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Negative Free Cash Flow (₹-15.62 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Kabra Drugs Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Kabra Drugs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Kabra Drugs LtdKabra Drugs Ltd...Selected✓ KABRADG • 524322 | 50.2/100 | ₹24.04₹24 | ₹51.49₹51.49 | 10.38Average 10.4 Average | 18.28%Good 18.28% Good | 20.80%Excellent 20.80% Excellent | 0.02Excellent 0.0 Excellent | 96.85%Excellent 96.85% Excellent | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Kabra Drugs Ltd Quarterly Performance
Latest quarterly metrics for KABRADG — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
171.79%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
96.85%
Compounded annual net profit growth over 5 years
Kabra Drugs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for KABRADG — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Kabra Drugs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Kabra Drugs Ltd (KABRADG) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Kabra Drugs Ltd
About KABRADG (Kabra Drugs Ltd)
Kabra Drugs Ltd is a dormant entity in the pharmaceutical sector, currently holding no active operational functions. Historically, Kabra Drugs Ltd participated in the manufacturing... and commercial exchange of pharmaceutical related goods, though these activities have ceased. The company's original ambition focused on permaculture, a sustainable agricultural system, hinting at an earlier diversification strategy into eco-friendly practices. This suggests a potential for incorporating environmentally conscious manufacturing processes should the company choose to reactivate. Established in 1989, Kabra Drugs Ltd has maintained its headquarters in Chennai, India, as its registered base. While currently inactive, the company's registration as a pharmaceutical entity provides a potential framework for future development within the industry. The existing infrastructure and knowledge base, however outdated, could offer a foundation for re-entry into the market, either through internal restructuring or external collaborations. The company's long-standing presence, even in dormancy, suggests a level of legacy and brand awareness that could be leveraged in any future endeavors. The current state of Kabra Drugs Ltd necessitates a significant reevaluation of its business model and strategic direction should it seek to revitalize its operations. Market analysis, investment in updated technology, and a renewed focus on regulatory compliance would be essential to compete effectively in the modern pharmaceutical landscape. The shift from active engagement to dormancy represents a turning point in the company's history, demanding bold leadership and innovative strategies to navigate the challenges and opportunities that lie ahead.
Company Details
Key Leadership
KABRADG Share Price: Frequently Asked Questions
What is the current share price of Kabra Drugs Ltd?
Kabra Drugs Ltd (KABRADG) trades at ₹24.04 on NSE and BSE. Market cap ₹51.49 (Cr). Educational data only.
What is the P/E ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has a P/E of 10.38x vs industry average 34.89x.
What is the Bull Run score for Kabra Drugs Ltd?
Kabra Drugs Ltd has a Bull Run score of 50.2/100 based on 25+ financial parameters.
Does Kabra Drugs Ltd pay dividends?
Kabra Drugs Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Kabra Drugs Ltd?
Kabra Drugs Ltd has ROE of 18.28%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Kabra Drugs Ltd?
Kabra Drugs Ltd has debt-to-equity of 0.02.
Is Kabra Drugs Ltd a good investment?
Bull Run gives Kabra Drugs Ltd a score of 50.2/100. This is not investment advice — consult a SEBI-registered advisor.